{"product_id":"phytotherapies-9781118268063","title":"Phytotherapies","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eCovering fundamentals and new developments in phytotherapy, this book combines pharmaceutical sciences and chemistry with clinical issues.\u003cbr\u003e \u003cbr\u003e  Helps readers better understand phytotherapy and learn the fundamentals of and how to analyze phytotherapeutic agents\u003cbr\u003e  Discusses phytotherapy in modern medicine, chemoprevention of disease, and alternatives to western medicines for specific diseases\u003cbr\u003e  Chapters summarizes the uses and applications of phytomedicines, by type like Chinese, Greco-Arab, Indian, European, and Ayurvedic\u003cbr\u003e  Includes international regulatory perspectives and discusses emerging regulations for various established and emerging markets\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eList of Contributors xvii\u003c\/p\u003e \u003cp\u003ePreface xxi\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Phytotherapies—Past, Present, and Future 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eIqbal Ramzan and George Q. Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Overview of Phytotherapy 1\u003c\/p\u003e \u003cp\u003e1.2 Preclinical Research on Phytotherapies 3\u003c\/p\u003e \u003cp\u003e1.3 Clinical Research on Phytotherapies 6\u003c\/p\u003e \u003cp\u003e1.4 Safety of Phytotherapies 8\u003c\/p\u003e \u003cp\u003e1.5 Profile of Research in Complementary Medicine 9\u003c\/p\u003e \u003cp\u003e1.6 Summary and Future Directions 12\u003c\/p\u003e \u003cp\u003eReferences 12\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Quality Control and Quality Assurance of Phytomedicines: Key Considerations, Methods, and Analytical Challenges 18\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eWai‐Ping Yau, Cheong Hian Goh, and Hwee‐Ling Koh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 18\u003c\/p\u003e \u003cp\u003e2.2 Key Considerations in QC\/QA of Phytomedicines 20\u003c\/p\u003e \u003cp\u003e2.3 Methods for QC\/QA of Phytomedicines 27\u003c\/p\u003e \u003cp\u003e2.4 Challenges 37\u003c\/p\u003e \u003cp\u003e2.5 Conclusions 40\u003c\/p\u003e \u003cp\u003eReferences 40\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Preclinical (\u003ci\u003eIn Vivo\u003c\/i\u003e) and Laboratory (\u003ci\u003eIn Vitro\u003c\/i\u003e) Evidence of Phytomedicine Efficacy 49\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMohi Iqbal Mohammed Abdul and Tom Hsun‐Wei Huang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction to Development of Drugs from Nature 49\u003c\/p\u003e \u003cp\u003e3.2 Use of \u003ci\u003eIn Vitro and in Vivo \u003c\/i\u003eModels in Herb Drug Research: Learning Thus Far 50\u003c\/p\u003e \u003cp\u003e3.3 Cardiovascular‐ and Stroke‐Related Diseases: \u003ci\u003eIn Vitro \u003c\/i\u003eand \u003ci\u003eIn Vivo \u003c\/i\u003eFocus 53\u003c\/p\u003e \u003cp\u003e3.4 Conclusions 60\u003c\/p\u003e \u003cp\u003eReferences 61\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Clinical Efficacy Trials with Natural Products and Herbal Medicines 65\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eChristina L. Nance\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 65\u003c\/p\u003e \u003cp\u003e4.2 Trials in Various Disease States 66\u003c\/p\u003e \u003cp\u003e4.3 Natural Product: Green Tea 73\u003c\/p\u003e \u003cp\u003e4.4 EGCG Clinical Trials 75\u003c\/p\u003e \u003cp\u003e4.5 Human Clinical Study: EGCG and HIV‐1 Infection 78\u003c\/p\u003e \u003cp\u003e4.6 Conclusion 80\u003c\/p\u003e \u003cp\u003eReferences 80\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Novel Formulations and Drug Delivery Systems for Phytotherapies 89\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eShengpeng Wang, Meiwan Chen, Qi (Tony) Zhou, and Hak‐Kim Chan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Limitations of Conventional Formulations for Herbal Medicines 89\u003c\/p\u003e \u003cp\u003e5.2 Crucial Issues of Developing Novel Delivery Systems for Herbal Medicines 91\u003c\/p\u003e \u003cp\u003e5.3 Novel Delivery Systems of Herbal Medicines 93\u003c\/p\u003e \u003cp\u003e5.4 Summary 96\u003c\/p\u003e \u003cp\u003eReferences 97\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Phytotherapies Used by Indigenous Populations 101\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eBradley S. Simpson and Susan J. Semple\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 101\u003c\/p\u003e \u003cp\u003e6.2 Phytotherapies of Indigenous Australians 103\u003c\/p\u003e \u003cp\u003e6.3 Challenges of a Changing Environment 114\u003c\/p\u003e \u003cp\u003e6.4 Conclusions 117\u003c\/p\u003e \u003cp\u003eReferences 118\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Phytotherapies from Traditional Chinese Medicine 122\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichael Rieder\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Traditional Chinese Medicine 122\u003c\/p\u003e \u003cp\u003e7.2 Key Concepts in Traditional Chinese Medicine 124\u003c\/p\u003e \u003cp\u003e7.3 Herbal Medicine and Traditional Chinese Medicine 126\u003c\/p\u003e \u003cp\u003e7.4 Issues in the Development of Phytotherapy from Traditional Chinese Medicine 130\u003c\/p\u003e \u003cp\u003e7.5 Phytotherapies Developed from Traditional Chinese Medicine 131\u003c\/p\u003e \u003cp\u003e7.6 Huang Qin Tang and the Development of PHY906 134\u003c\/p\u003e \u003cp\u003e7.7 Ginseng 136\u003c\/p\u003e \u003cp\u003e7.8 Moving Forward 138\u003c\/p\u003e \u003cp\u003eReferences 138\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Integrating Traditional Greco‐Arab and Islamic Diet and Herbal Medicines in Research and Clinical Practice 142\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eBashar Saad\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 142\u003c\/p\u003e \u003cp\u003e8.2 Food Therapy in Greco‐Arab and Islamic Medicine 147\u003c\/p\u003e \u003cp\u003e8.3 Medicinal Plants 157\u003c\/p\u003e \u003cp\u003eReferences 177\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Evolution of Herbal Medicines in Europe and its Relationship with Modern Medicine 183\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eElizabeth M. Williamson and Kelvin Chan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Background 183\u003c\/p\u003e \u003cp\u003e9.2 Historical Perspective 184\u003c\/p\u003e \u003cp\u003e9.3 European Herbal Medicine: Relationship with Modern Medicine 194\u003c\/p\u003e \u003cp\u003e9.4 Summary 194\u003c\/p\u003e \u003cp\u003eReferences 196\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Chemical Classification and Chemistry of Phytotherapeutics Constituents 199\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePei H. Cui and Colin C. Duke\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 199\u003c\/p\u003e \u003cp\u003e10.2 Phytochemicals 201\u003c\/p\u003e \u003cp\u003e10.3 Other Phytochemicals 215\u003c\/p\u003e \u003cp\u003e10.4 Medicinal Effects Relating to Dietary Intake 217\u003c\/p\u003e \u003cp\u003e10.5 Natural Products as Leads for Drug Development 223\u003c\/p\u003e \u003cp\u003e10.6 Summary 230\u003c\/p\u003e \u003cp\u003eReferences 230\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Therapeutic Potential of Ginsenosides in Management of Atherosclerosis 236\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eXiao‐Jing Zhang, Huanxing Su, Yi-Tao Wang, and Jian-Bo Wan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 236\u003c\/p\u003e \u003cp\u003e11.2 Chemical Diversity of Ginsenosides and Distribution 238\u003c\/p\u003e \u003cp\u003e11.3 Anti‐Atherosclerotic Effects of Ginsenosides 240\u003c\/p\u003e \u003cp\u003e11.4 Underlying Mechanisms of Ginsenosides Against Atherosclerosis 244\u003c\/p\u003e \u003cp\u003e11.5 Conclusions and Future Perspectives 258\u003c\/p\u003e \u003cp\u003eAcknowledgments 258\u003c\/p\u003e \u003cp\u003eReferences 258\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Phytotherapy Pharmacophores for Major Cellular Drug Targets 268\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJennifer A. Ong, Paul W. Groundwater, and David E. Hibbs\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 268\u003c\/p\u003e \u003cp\u003e12.2 What is a Pharmacophore? 269\u003c\/p\u003e \u003cp\u003e12.3 Pharmacophore Models of Cardiovascular Drugs 270\u003c\/p\u003e \u003cp\u003e12.4 Pharmacophore Models for Anticancer Drugs 285\u003c\/p\u003e \u003cp\u003e12.5 Pharmacophore Models for Anti‐Inflammatory Drugs 290\u003c\/p\u003e \u003cp\u003e12.6 Pharmacophore Models for Anti‐Infective Drugs 297\u003c\/p\u003e \u003cp\u003e12.7 Pharmacophore Models for Neurological Drugs 299\u003c\/p\u003e \u003cp\u003e12.8 Pharmacophore Models for Miscellaneous Drugs 305\u003c\/p\u003e \u003cp\u003e12.9 Conclusions 309\u003c\/p\u003e \u003cp\u003eReferences 309\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Use of Kava as a Phytotherapeutic Agent and Kava‐Related Hepatotoxicity 312\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDong Fu and Iqbal Ramzan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 312\u003c\/p\u003e \u003cp\u003e13.2 Active Components in Kava 313\u003c\/p\u003e \u003cp\u003e13.3 Therapeutic Applications of Kava 314\u003c\/p\u003e \u003cp\u003e13.4 Pharmacology of Kava 314\u003c\/p\u003e \u003cp\u003e13.5 Side Effects of Kava 317\u003c\/p\u003e \u003cp\u003e13.6 Hepatotoxicity of Kava 318\u003c\/p\u003e \u003cp\u003e13.7 Summary and Future Challenges 322\u003c\/p\u003e \u003cp\u003eReferences 323\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Phytotherapies as New Drug Sources: Gossypol and Curcumin 330\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eVivian Wan Yu Liao, Rajeshwar Narlawar, David E. Hibbs, and Paul W. Groundwater\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Botanical Sources of Gossypol and Curcumin 330\u003c\/p\u003e \u003cp\u003e14.2 Stereoisomerism, Tautomerism, and Reactivity 332\u003c\/p\u003e \u003cp\u003e14.3 Biological Activity of Gossypol and its Analogues 337\u003c\/p\u003e \u003cp\u003e14.4 Biological Activity of Curcumin and its Analogues 346\u003c\/p\u003e \u003cp\u003eReferences 360\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Phytotherapies for the Management of Obesity and Diabetes 370\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichel Rapinski and Alain Cuerrier\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 370\u003c\/p\u003e \u003cp\u003e15.2 Plants from the North American Pharmacopoeia 372\u003c\/p\u003e \u003cp\u003e15.3 Pharmacological Screening: Providing Empirical Evidence for Phytotherapies 379\u003c\/p\u003e \u003cp\u003e15.4 Community‐Based Participation: Developing Phytotherapies from Traditional Knowledge 385\u003c\/p\u003e \u003cp\u003e15.5 Conclusions 387\u003c\/p\u003e \u003cp\u003eReferences 387\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Phytotherapeutics for Cancer Therapy 394\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDaniel M.‐Y. Sze, Hao Liu, Maureen V. Boost, Raimond Wong, and Stephen Sagar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 394\u003c\/p\u003e \u003cp\u003e16.2 Anticancer Phytotherapeutics With NK Enhancement 395\u003c\/p\u003e \u003cp\u003e16.3 Conclusions 423\u003c\/p\u003e \u003cp\u003eReferences 425\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Phytomedicines for Fatty Liver Disease and Functional Gastrointestinal Conditions 429\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGeorge Q. Li, Moon‐Sun Kim, Fangming Jin, and Jun‐Lae Cho\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 429\u003c\/p\u003e \u003cp\u003e17.2 Phytomedicines for FLD 430\u003c\/p\u003e \u003cp\u003e17.3 Phytomedicines for IBS 439\u003c\/p\u003e \u003cp\u003e17.4 Phytomedicines for Constipation 444\u003c\/p\u003e \u003cp\u003e17.5 Summary and Future Perspectives 448\u003c\/p\u003e \u003cp\u003eReferences 448\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Phytomedicines for Inflammatory Conditions 464\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSigrun Chrubasik‐Hausmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Traditional Medicines for Inflammatory Conditions in Europe 464\u003c\/p\u003e \u003cp\u003e18.2 Twenty‐First‐Century Update on Paids 465\u003c\/p\u003e \u003cp\u003e18.3 Oral Extracts from \u003ci\u003eSalix \u003c\/i\u003eSpecies 465\u003c\/p\u003e \u003cp\u003e18.4 Oral Extracts from \u003ci\u003eHarpagophytum procumbens \u003c\/i\u003e468\u003c\/p\u003e \u003cp\u003e18.5 Oral Avocado–Soybean Unsaponifiables 469\u003c\/p\u003e \u003cp\u003e18.6 Oral Extracts From \u003ci\u003eTripterygium wilfordii \u003c\/i\u003e473\u003c\/p\u003e \u003cp\u003e18.7 Oral Paids Containing Unsaturated Fatty Acids 475\u003c\/p\u003e \u003cp\u003e18.8 Other Oral Paids 476\u003c\/p\u003e \u003cp\u003e18.9 Topical Paids 477\u003c\/p\u003e \u003cp\u003eReferences 478\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Phytotherapies for Infectious Diseases: Are These Really Useful? 483\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGail B. Mahady, Gabrielle Escalante, Pooja Mikkilineni, Laura J. Mahady, Temitope O. Lawal, and Bolanle A. Adeniyi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eThe History of Medicine 483\u003c\/p\u003e \u003cp\u003e19.1 Introduction 484\u003c\/p\u003e \u003cp\u003e19.2 Historical Precedent for Natural Products as Antimicrobial Drugs 486\u003c\/p\u003e \u003cp\u003e19.3 Are Phytotherapies Useful for the Treatment of Infectious Diseases? 487\u003c\/p\u003e \u003cp\u003e19.4 Naturally Occurring Compounds that may Reduce Zoonosis 495\u003c\/p\u003e \u003cp\u003e19.5 Synergistic and Additive Effects with Antibiotics 496\u003c\/p\u003e \u003cp\u003e19.6 New Emerging Infectious Diseases and those with no Known Treatments 496\u003c\/p\u003e \u003cp\u003e19.7 SARS 497\u003c\/p\u003e \u003cp\u003e19.8 Reducing MRSA Carriage 498\u003c\/p\u003e \u003cp\u003e19.9 Conclusions 499\u003c\/p\u003e \u003cp\u003eReferences 500\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Phytomedicines for CNS Disorders: Safety Issues for use with Antiepileptic Drugs 504\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSophia Yui Kau Fong, Rosina Yau Mok, Qiong Gao, Yin Cheong Wong, and Zhong Zuo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20.1 Introduction 504\u003c\/p\u003e \u003cp\u003e20.2 Methodology of Systematic Literature Search 506\u003c\/p\u003e \u003cp\u003e20.3 Pharmacokinetic Interactions 506\u003c\/p\u003e \u003cp\u003e20.4 Pharmacodynamic Interactions 512\u003c\/p\u003e \u003cp\u003e20.5 Conclusions 524\u003c\/p\u003e \u003cp\u003eReferences 524\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Phytotherapies: Drug Interactions in Cancer 536\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAndrew J. McLachlan and Stephen J. Clarke\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21.1 Introduction 536\u003c\/p\u003e \u003cp\u003e21.2 Use of Herbal and Complementary Medicines by People Living with Cancer 537\u003c\/p\u003e \u003cp\u003e21.3 Mechanisms of Phytotherapy–Drug Interactions 538\u003c\/p\u003e \u003cp\u003e21.4 Selected Examples of Phytotherapy Medicines that have the Potential to Cause Drug Interactions in Cancer 540\u003c\/p\u003e \u003cp\u003e21.5 Future Perspectives: Need for Evidence and Advice to Cancer Patients and Physicians 546\u003c\/p\u003e \u003cp\u003e21.6 Conclusions 547\u003c\/p\u003e \u003cp\u003eAcknowledgments 547\u003c\/p\u003e \u003cp\u003eConflict of Interest 547\u003c\/p\u003e \u003cp\u003eReferences 547\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Quality Use of Medicines: Considerations in Phytotherapy 554\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLynn Weekes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22.1 Introduction 554\u003c\/p\u003e \u003cp\u003e22.2 Relevance of Qum for Herbal Medicines 556\u003c\/p\u003e \u003cp\u003e22.3 Use of Phytotherapies by Consumers 558\u003c\/p\u003e \u003cp\u003e22.4 Consumer Attitudes and Beliefs about Herbal Medicines 559\u003c\/p\u003e \u003cp\u003e22.5 Applying the Qum Framework to Phytotherapies 561\u003c\/p\u003e \u003cp\u003e22.6 Building Blocks for Quality Use of Herbal Medicines 566\u003c\/p\u003e \u003cp\u003e22.7 Conclusion 570\u003c\/p\u003e \u003cp\u003eReferences 570\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Intellectual Property and Patent Issues with Phytotherapy Products 573\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGint Silins, Jennifer Tan, and Kelvin Chan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23.1 Introduction 573\u003c\/p\u003e \u003cp\u003e23.2 IP Rights—Phyto‐Industry 575\u003c\/p\u003e \u003cp\u003e23.3 Brief Overview of Patents and the Patenting Process 578\u003c\/p\u003e \u003cp\u003e23.4 Other Types of IP Rights 585\u003c\/p\u003e \u003cp\u003e23.5 Patenting Trends for Phytotherapeutics 587\u003c\/p\u003e \u003cp\u003e23.6 Traditional Knowledge and IP Rights 587\u003c\/p\u003e \u003cp\u003eDisclaimer 589\u003c\/p\u003e \u003cp\u003eReferences 590\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 International Regulatory Status of Phytotherapies 593\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eErnest V. Linek\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24.1 Introduction 593\u003c\/p\u003e \u003cp\u003e24.2 Specific Country Regulations 596\u003c\/p\u003e \u003cp\u003e24.3 Future of Phytotherapies: World Health Organization (WHO) 631\u003c\/p\u003e \u003cp\u003eFurther Reading 634\u003c\/p\u003e \u003cp\u003eIndex 635\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49406844141911,"sku":"9781118268063","price":152.06,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118268063.jpg?v=1730497314","url":"https:\/\/bookcurl.com\/products\/phytotherapies-9781118268063","provider":"Book Curl","version":"1.0","type":"link"}